







Silesian Park of Medical Technologies Kardio-Med Silesia Sp. z o. o. M. Curie-Skłodowskiej Street 10c, 41-800 Zabrze

L.Dz. 442/KL/21

Zabrze, dn. 16.02.2022 r.

Participants in the proceedings

Regarding: the procurement procedure for "Supply of products for tests" (4/Z/22) under the project "entitled "Personalized, liposome-based small inhibitory RNA therapy of acute myeloid leukemias (OBS / AML)" Project co-financed by the European Regional Development Fund under the Regional Operational Program of the Silesian Voivodeship for 2014-2020 from Measure 1.2. Research, development and innovation in enterprises

According to the content of chapter X, point 2 of the TERMS AND CONDITIONS OF THE CONTRACT in connection with the question submitted by the Contractors to the TERMS AND CONDITIONS OF THE CONTRACT regarding the above-mentioned proceedings:

1. According to part no. 2: chap. VI point 1.5

Due to the specificity of the products listed in parts 8 and 12, we would like to ask you to withdraw from the delivery of folders / leaflets / catalogs of the offered subject of the contract within 3 days, in exchange for the expression consent for the Ordering Party to independently download from the manufacturer's website detailed descriptions of the subject of the contract in English or to provide the required documents in English upon request.

The Ordering Party answers: The Ordering Party agrees.

According to parts no. 8 and 12: chap. XIV point 2 of the TERMS AND CONDITIONS OF THE CONTRACT

Does the Ordering Party consent to the withdrawal from the necessity of the Contractor's appearance within 3 working days from the date of notification of the selection of the best offer in order to sign the contract and will consent to send the arrangement by post or e-mail, and then returning the signed document by post.

The Ordering Party answers: The Ordering Party agrees



3. It concerns the template of the agreement, par. 3 sec. 4

Will the Ordering Party allow the delivery of the invoice by e-mail in pdf format to the e-mail address provided by the Ordering Party in the order.

<u>The ordering Party answers</u>: In accordance with TERMS AND CONDITIONS OF THE CONTRACT.

4. Will the Ordering Party agree to offer a 60-day payment period.

The Ordering Party answers: The awarding entity agrees.

5. Concerns the specimen agreement, par. 8 sec. 2

Does the Ordering Party confirm that it understands the offered validity period as the warranty period of the reagents / antibodies offered.

<u>The Ordering Party answers</u>: The Ordering Party confirms that by the warranty period of the reagents / antibodies offered, it understands the offered expiry date.

6. Concerns the model agreement, paragraph 5 sec. 1 and 2

We ask for change the calculation of contractual penalties for delay in the delivery of goods on the value of the goods actually delivered with delay, and not on the value of the entire contract.

The Ordering Party answers: The awarding entity does not consent.

7. Concerns part no. 8 pos. 1

In the task 8 pos. 2 provided by the Ordering Party, Product Code 561816 is a monoclonal antibody against the human CD33 antigen conjugated with PE derived from the WM53 clone, 25 tests which significantly differs from the given product description. Therefore, please clarify whether the Ordering Party in position 1 means an APC-conjugated anti-human CD33 monoclonal antibody derived from the WM53 clone, 100 tests, not worse than 551378 or monoclonal antibody PE-conjugated anti-human CD33 antigen derived from clone WM53, 100 tests, not worse than 555450.

<u>The Ordering Party answers</u>: the ordering party in position 1 represents an APC-conjugated anti-human CD33 monoclonal antibody derived from the WM53 clone, 100 tests, not worse then 551378.



8. Can the contracting authority specify what kind of oligonucleotide is meant in the content of task 7? In the title of the query itself, there are inhibitory RNAs, while in the content of the task itself, there is only information about the valuation of oligonucleotides and costs per 1 nucleotide, without specifying whether it is DNA or RNA.

<u>The Ordering Party answers</u>: The inquiry concerns the synthesis of both RNA and DNA (mainly RNA).

At the same time, according to the content of Chapter X, point 3 of the TERMS AND CONDITIONS OF THE CONTRACT, the Ordering Party informs that the deadline for submitting bids will be extended

New deadline for submitting offers: 02/03/2022 at 10.00 a.m.
New offer opening date: 02/03/2022 at 10.30 a.m.

Adam Konka

Chairman of the Board Silesian Park of Medical Technologies Kardio-Med Silesia Sp. z o. o.

M

M